Further investigation into the immunomodulatory effects of GLP-1 RAs on NASH pathogenesis within the adaptive immune response framework could enhance confidence in this treatment approach. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatohepatitis.